Drug Database
FL

fluorouracil (Carac, microsponge)

✓ Approved

Heron Therapeutics, Inc. · TYMS · 小分子

什么是 fluorouracil?

fluorouracil 是一种小分子,由Heron Therapeutics, Inc.研发。该药已获批,用于治疗相关适应症,给药途径:Transdermal。

药物档案

商品名Carac, microsponge
公司Heron Therapeutics, Inc.
药物类别小分子
分子靶点TYMS
给药途径Transdermal
状态Approved

作用机制

分子靶点

fluorouracil 作用于 1 个分子靶点:

TYMSthymidylate synthetase (DKCD, TMS)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

fluorouracil 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Skin and subcutaneous tissue disordersActinic keratosis✓ Approved

相关研究文献

PubMedNPJ precision oncology2026-11-19

Shared evolutionary trajectories underlying carcinogenesis and metastasis in biliary tract cancer.

Kang Minsu M, Lee Ju Hyun JH, Na Hee Young HY, Kim Ji-Won JW et al.

The evolutionary dynamics of biliary tract cancer (BTC)-from precancerous transformation through metastatic dissemination and recurrence-remain poorly understood. We performed multi-regional and longitudinal whole-exome sequencing of 55 tumor specimens and 17 matched normals from 17 patients to reconstruct patient-specific phylogenetic trees and mutational signatures. TP53 (41.2%), KRAS (29.4%), and SMAD4 (23.5%) were the most frequently altered genes in primary tumors. Precancerous biliary intraepithelial neoplasia already harbored canonical driver mutations such as TP53 and KRAS, showing early branching and selective sweeps during malignant transition. During metastasis, distinct subclones expanded more than fivefold in 15 of 17 patients, frequently harboring driver-like alterations (e.g., NFKB1, MAPK7, PIK3C2A). Postoperative recurrences retained the phylogenetic structure of the primary tumor, supporting polyclonal rather than single-cell seeding. Mutational signatures associated with 5-fluorouracil (SBS17b) and platinum (SBS35) were enriched in recurrent/metastatic lesions, suggesting that chemotherapy may shape the tumor mutational landscape. Druggable targets-including ERBB2 amplification and KRAS mutations-were maintained through recurrence and metastasis when present at diagnosis. These findings reveal a consistent evolutionary program in BTC, encompassing early clonal diversification, subclonal expansion during metastasis, and polyclonal recurrence, underscoring the need for evolution-informed therapeutic strategies that address both clonal and subclonal alterations.

PMID 43052378
阅读全文 →
PubMedCancer immunology, immunotherapy : CII2026-11-19

Tumor-associated antigen-reactive T cells and clinical outcomes in head and neck squamous cell carcinoma treated with pembrolizumab plus chemotherapy.

Sato Ryosuke R, Sakaue Shota S, Ominato Hisataka H, Inoue Takahiro T et al.

Blood-based biomarkers associated with clinical outcomes in patients with head and neck squamous cell carcinoma (HNSCC) treated with pembrolizumab plus chemotherapy remain poorly defined. We investigated 38 patients with HNSCC treated with pembrolizumab plus 5-fluorouracil and platinum (FP). Baseline systemic inflammation and immune status were assessed using routine laboratory parameters. Peripheral blood mononuclear cells were analyzed by flow cytometry to assess exhaustion- and activation-associated markers on CD4⁺ and CD8⁺ T cells, including CD38, Tim-3, PD-1, and ICOS. Tumor-associated antigen (TAA)-reactive immune responses were evaluated by interferon-γ production following stimulation with epidermal growth factor receptor (EGFR)- and c-Met-derived peptides. PD-L1 CPS positivity, elevated neutrophil-to-lymphocyte ratio, and higher frequencies of CD8⁺CD38⁺ T cells were associated with clinical outcomes, with similar trends observed for selected inflammatory and peripheral T-cell activation/exhaustion-associated markers. Tumor-associated antigen-reactive immune responses were detected in a subset of patients and were associated with prolonged progression-free survival, while EGFR peptide reactivity was additionally associated with improved overall survival. In this exploratory study, immune reactivity to TAAs was associated with favorable clinical outcomes in patients receiving pembrolizumab plus FP. Together with systemic inflammation and peripheral T-cell activation/exhaustion markers, these findings support further evaluation of integrated blood-based immune profiling, including TAA-reactive immune responses, as candidate biomarkers in larger prospective cohorts.

PMID 43052553
阅读全文 →
PubMedJournal of cosmetic dermatology2026-11-18

A Sequential Treatment of Keloids: Multiple-Hole Punch Excision Combined With Superficial Radiation and Drug.

Gong Zhicheng Z, Jing Wenwen W, Zhang Zhenhua Z, Rao Wenbin W et al.

Dense and multiple keloids present significant therapeutic challenges due to their stubborn nature and high recurrence rates. Although various treatment options exist, optimizing current approaches and integrating them into a rational, systematic regimen for keloid management remains a difficult clinical problem. This study aims to establish an effective multimodal sequential treatment protocol for patients with dense, multiple keloids. A total of 87 patients with 285 keloid lesions were enrolled from September 2023 to April 2024. All cases underwent a sequential treatment: Stage I involved drug-assisted multiple-hole punch excision followed by adjuvant superficial radiotherapy; Stage II consisted of periodic intralesional injections of betamethasone and 5-fluorouracil. Clinical outcomes, recurrence, and adverse events were evaluated at 12-month follow-up. The POSAS and VSS scores were recorded at each time point. At 12 months post-treatment, marked improvement was achieved in 78 patients (89.66%), with improvement in 7 (8.04%) and ineffective results in 2 (2.30%). The POSAS and VSS scores were recorded before treatment and at follow-up points at 30, 60, 90, 180, and 360 days. All patients developed varying degrees of local hyperpigmentation within 2 months after Stage I of multi-hole punch excision. In 80.75% of cases, the hyperpigmentation resolved within 3 months following Stage I, with the longest duration of resolution being 12 months. During Stage I, four cases of localized ulcers and five instances of acute radiation dermatitis appeared. All adverse reactions were effectively alleviated. No other adverse reactions occurred. This sequential treatment protocol offers a practical, minimally invasive, and effective option for patients with multiple, dense keloids.

PMID 43047096
阅读全文 →
PubMedJournal of molecular graphics & modelling2026-11-17

Surface-engineered Mo2B2 MBene for controlled 5-fluorouracil delivery: A DFT insight into adsorption and electronic mechanisms.

Al-Senani Ghadah M GM, Sakr Mahmoud A S MAS, Al-Qahtani Salhah D SD, Alkhamisi Manal M MM et al.

Density functional theory (DFT) calculations were performed to evaluate pristine and functionalized MBene Mo2B2 (F, O, S, H) as nanocarriers for anticancer drugs 5-fluorouracil (5Flu) and metformin (Met). Surface functionalization significantly modulates structural stability, electronic properties, and drug-surface interactions. Among all systems, O-functionalization exhibits the highest stability and strongest electronic tuning. Adsorption analysis shows that 5Flu displays moderate and tunable binding, with Mo2B2-O achieving near-optimal adsorption energy, ensuring a balance between drug loading and controlled release. In contrast, Met exhibits excessively strong chemisorption on all surfaces, limiting its release capability. Electronic (HOMO-LUMO, DOS) and NBO analyses reveal enhanced charge transfer and orbital hybridization in O-functionalized systems, while NCI results indicate van der Waals-dominated interactions for 5Flu and stronger donor-acceptor interactions for Met. Optical analysis demonstrates tunable absorption and enhanced charge-transfer characteristics upon functionalization. Overall, Mo2B2-O emerges as a promising platform for efficient and controlled 5Flu delivery in cancer therapy.

PMID 43044160
阅读全文 →
PubMedInternational journal of radiation oncology, biology, physics2026-11-17

Mitomycin C/5-Fluorouracil Versus Cisplatin/5-Fluorouracil With Hyperfractionated Accelerated Radiotherapy in Locally Advanced Head and Neck Cancer: The ARO 04-01/AHMO Trial.

Budach V V, Werner J J, Wittlinger M M, Fietkau R R et al.

Cisplatin-based concurrent chemoradiotherapy (CRT) is the standard for locally advanced head and neck squamous cell carcinoma (HNSCC). For cisplatin (CDDP)-ineligible patients, mitomycin C/5-fluorouracil (MMC/5-FU) is the most common alternative, but randomized comparisons are lacking. We compared MMC/5-FU with CDDP/5-FU as concurrent partners of hyperfractionated-accelerated radiotherapy (HART) in unresectable, locally advanced HNSCC. In this multicenter phase III trial, 364 patients with stage IVA/IVB (UICC TNM 6th edition) oropharyngeal or hypopharyngeal HNSCC were randomized 1:1 to HART (72 Gy/6 weeks) plus either weekly CDDP 30 mg/m² (n=182) or MMC 10 mg/m² on days 5 and 36 (n=182), both with continuous-infusion 5-FU 600 mg/m²/d on days 1-5. The primary endpoint was overall survival (OS); secondary endpoints included freedom from progression (FFP), freedom from distant metastasis (FFDM), local, regional and locoregional control, and toxicity, analyzed by Kaplan-Meier and, post hoc, in a competing-risk framework. After a median follow-up of 87 months, CDDP/5-FU was not superior for OS (10-year OS 23% vs. 18%; hazard ratio [HR] 0.89, 95% CI 0.69-1.15; log-rank p=0.418). In the competing-risk analysis, CDDP/5-FU reduced distant metastasis (5-year cumulative incidence 25.9% vs. 36.1%; subdistribution HR 0.66, 95% CI 0.45-0.96; p=0.031) and progression (45.6% vs. 56.3%; subdistribution HR 0.73, 95% CI 0.55-0.98; p=0.037). Kaplan-Meier estimates were directionally consistent but not significant (10-year FFDM 66% vs. 52%; HR 0.69, 95% CI 0.48-1.02; p=0.060; FFP HR 0.79, 95% CI 0.59-1.05); local, regional and locoregional control (HR 0.80-1.01) and toxicity profiles did not differ. Serum creatinine (p<0.001) and the AE/SAE rate (24.2% vs. 15.4%; p=0.048) were higher with CDDP. ARO 04-01/AHMO did not show superiority of CDDP/5-FU over MMC/5-FU for overall survival. CDDP-based CRT remains the established standard for fit patients; MMC/5-FU is a safe and effective alternative with comparable overall survival and measurably lower nephrotoxicity and cumulative AE/SAE burden for CDDP-contraindicated patients. DRKS00040575.

PMID 43044775
阅读全文 →
PubMedJournal of enzyme inhibition and medicinal chemistry2026-11-17

Tramadol potentiates chemotherapy efficacy in hepatocellular carcinoma cells.

Fan Hsiu-Lung HL, Liu Shu-Ting ST, Wu Zih-Syuan ZS, Huang Yi-Hsuan YH et al.

Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third leading cause of cancer-related deaths, leading to poor responses to chemotherapy. Cancer-related pain affects up to 90% of these patients, significantly impairing their quality of life. Tramadol, a prescribed analgesic for cancer pain, has shown anti-tumour effects in various malignancies, yet its potential in HCC remains largely unexplored. In this study, we investigated tramadol's anti-proliferative, pro-apoptotic, and autophagy-inducing effects in HepG2, Hep3B, and Huh7 cell lines. Tramadol significantly inhibits cell proliferation in a dose-dependent manner, leading to a reduction in the S-phase and subG1 phase accumulation. It induces apoptosis in HepG2 and Hep3B, increases late apoptosis/necrosis, and enhances autophagy. Additionally, tramadol increased the cytotoxicity of cisplatin and 5-fluorouracil, with significant reductions in their IC50 values. Overall, tramadol inhibits HCC growth, promotes apoptosis, and enhances chemotherapy efficacy, suggesting it could be a dual-benefit therapeutic strategy for HCC.

PMID 43040933
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多fluorouracil